Drug-induced liver injury

Mayo Clinic Proceedings

Volumn 89, Issue 1, 2014, Pages 95-106

  Leise, Michael D ^a   Poterucha, John J ^a   Talwalkar, Jayant A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMOXICILLIN PLUS CLAVULANIC ACID; BILIRUBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN TYROSINE KINASE INHIBITOR; QUINOLONE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHRONIC LIVER DISEASE; DIET SUPPLEMENTATION; DRUG DOSE; GENETIC PREDISPOSITION; HERBAL MEDICINE; HUMAN; INCIDENCE; LIPOPHILICITY; LIVER METABOLISM; PROGNOSIS; REVIEW; RISK FACTOR; SEX DIFFERENCE; TOXIC HEPATITIS;

EID: 84893148216     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.09.016     Document Type: Review

References (59)

1. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451-455.
2. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512-521.
3. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of druginduced liver injury in the United States. Gastroenterology. 2008;135(6):1924-1934, 1934.e1-4.
4. Suk KT, Kim DJ, Kim CH, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol. 2012; 107(9):1380-1387.
5. Bjornsson ES, BergmannOM, BjornssonHK, KvaranRB, Olafsson S. Incidence, presentation, and outcomes in patients with druginduced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419-1425, 1425.e1-3; quiz e19-20.
6. Zhou Y, Yang L, Liao Z, He X, Zhou Y, Guo H. Epidemiology of drug-induced liver injury in China: a systematic analysis of the Chinese literature including 21 789 patients. Eur J Gastroenterol Hepatol. 2013;25(7):825-829.
7. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Int Med. 2002;137(12):947-954.
8. Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065-2076.
9. Danan G, Benichou C. Causality assessment of adverse reactions to drugseI. A novel method based on the conclusions of international consensus meetings: application to druginduced liver injuries. J Clin Epidemiol. 1993;46(11):1323-1330.
10. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52(2):730-742.
11. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56(4):958-976.
12. Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol. 2011;9(6):517-523. e3.
13. Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558-564. e3.
14. Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51(6):2040-2048.
15. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis. 2007;11(3): 477-505, v.
16. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf. 2007;30(4):277-294.
17. Schenker S, Bay M. Drug disposition and hepatotoxicity in the elderly. J Clin Gastroenterol. 1994;18(3):232-237.
18. De Valle MB, Av Klinteberg V, Alem N, Olsson R, Bjornsson E. Drug-induced liver injury in a Swedish University hospital outpatient hepatology clinic. Aliment Pharmacol Ther. 2006;24(8): 1187-1195.
19. Hartleb M, Biernat L, Kochel A. Drug-induced liver damage e a three-year study of patients from one gastroenterological department. Med Sci Monit. 2002;8(4):CR292-CR296.
20. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49(6):2001-2009.
21. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10(8):1018-1023.
22. Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB. Acetaminophen hepatotoxicity in alcoholics. A therapeutic misadventure. Ann Int Med. 1986;104(3):399-404.
23. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology. 1995;22(3):767-773.
24. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA. 1994;272(23): 1845-1850.
25. Nyfors A. Liver biopsies from psoriatics related to methotrexate therapy Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand A. 1977;85(4): 511-518.
26. Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drugrelated liver dysfunction in chronic hepatitis B infection. Hepatology. 2000;31(1):201-206.
27. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74-80.
28. Fromenty B. Drug-induced liver injury in obesity. J Hepatol. 2013;58(4):824-826.
29. Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47(6):2003-2009.
30. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for druginduced liver injury. Hepatology. 2013;58(1):388-396.
31. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010;51(2):615-620.
32. Donaldson PT, Daly AK, Henderson J, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to coamoxiclav-induced liver injury. J Hepatol. 2010;53(6):1049-1053.
33. Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)-B57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillininduced liver injury. Hepatology. 2013;57(2):727-739.
34. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007;132(1):272-281.
35. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35(4):883-889.
36. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther. 1991; 49(1):13-17.
37. Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics. 2007;17(1):47-60.
38. Kuniholm MH, Purcell RH, McQuillan GM, Engle RE, Wasley A, Nelson KE. Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis. 2009;200(1):48-56.
39. Davern TJ, Chalasani N, Fontana RJ, et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology. 2011;141(5):1665-1672. e1-9.
40. Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther. 2007;26(10):1429-1435.
41. Starkey Lewis PJ, Dear J, Platt V, et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology. 2011;54(5):1767-1776.
42. Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013; 368(18):1685-1694.
43. Bell LN, Vuppalanchi R, Watkins PB, et al. Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2012;35(5):600-612.
44. Khandelwal N, James LP, Sanders C, Larson AM, Lee WM; Acute Liver Failure Study Group. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology. 2011;53(2):567-576.
45. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716-2724.
46. Gallagher P, Barry P, O'Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007;32(2):113-121.
47. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010;105(5):978-980.
48. Cohen DE, Anania FA, Chalasani N; National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists.AmJ Cardiol. 2006;97(8A):77C-81C.
49. Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374-380.
50. Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36(7):491-503.
51. Ghabril M, Fontana R, Rockey D, Jiezhun G, Chalasani N. Druginduced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience. J Clin Gastroenterol. 2013;47(6):553-558.
52. Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013; 37(1):3-17.
53. Bohan TP, Helton E, McDonald I, et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 2001;56(10):1405-1409.
54. LeeWM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856-864, 864.e1.
55. Zimmerman H. Drug-Induced Liver Disease. New York: Appleton-Century- Crofts; 1978.
56. Bjornsson E, Olsson R.Outcome and prognosticmarkers in severe drug-induced liver disease. Hepatology. 2005;42(2):481-489.
57. Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics. 1975;55(6):871-876.
58. Strnad P, Zhou Q, Hanada S, et al. Keratin variants predispose to acute liver failure and adverse outcome: race and ethnic associations. Gastroenterology. 2010;139(3):828-835, 835.e1-3.
59. Remien CH, Adler FR, Waddoups L, Box TD, Sussman NL. Mathematical modeling of liver injury and dysfunction after acetaminophen overdose: early discrimination between survival and death. Hepatology. 2012;56(2):727-734.